MindMed, a biomedical company that develops psychedelic-based products for brain disorders, secured $50 million

MindMed, a biomedical company that develops psychedelic-based products for brain disorders, secured $50 million The company says it will help them in areas such as their Phase 2b study of MM-120 (their optimized form of LSD) for the treatment of generalized anxiety disorder later this year. Read the article on Business Wire > Read More from the Global Wellness News ™

Why I Attend the GWS – A Message from Freddie Moross

The 17th Annual Global Wellness Summit | November 6-9 | Doha, Qatar Why I Attend the GWS? A Message from Freddie Moross “I have had the privilege of getting to know some of you over the last couple years and look forward to meeting more in due course. I greatly appreciate GWS and GWI, it is an incredible community and has been a valuable resource…